CA125 在预测胰腺癌的可切除性方面优于 CA19-9。
CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
机构信息
Pancreatic Cancer Institute, Fudan University, No. 270, Dong'An Road, Xuhui District, Shanghai, 200032, China.
出版信息
J Gastrointest Surg. 2013 Dec;17(12):2092-8. doi: 10.1007/s11605-013-2389-9. Epub 2013 Oct 22.
BACKGROUND
Although carbohydrate antigen 19-9 (CA19-9) has been reported as a biomarker to predict the resectability of pancreatic cancer, several limitations have restricted its clinical use.
METHODS
The potential of several serum tumor markers (CA19-9, CA125, CA50, CA242, CA724, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP)) to predict the resectability of pancreatic cancer was evaluated by receiver operating characteristic (ROC) analysis in a series of 212 patients with proven pancreatic cancer.
RESULTS
Compared with other tumor markers including CA19-9, CA125 has a superior predictive value (CA19-9, ROC area 0.66, cutoff value 289.40 U/mL; CA125, ROC area 0.81, cutoff value 19.70 U/mL). In addition, for patients with unresectable diseases misjudged by CT as resectable, the percentage of CA125 over selected cutoff value was higher than that of CA19-9 (CA19-9, 70.27 %; CA125, 81.08 %).
CONCLUSION
CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. Aberrant high levels of CA125 may indicate unresectable pancreatic cancer.
背景
尽管糖类抗原 19-9（CA19-9）已被报道为预测胰腺癌可切除性的生物标志物，但仍存在一些限制，限制了其临床应用。
方法
通过对 212 例经证实的胰腺癌患者进行受体操作特征（ROC）分析，评估了几种血清肿瘤标志物（CA19-9、CA125、CA50、CA242、CA724、癌胚抗原（CEA）和甲胎蛋白（AFP））预测胰腺癌可切除性的潜力。
结果
与 CA19-9 等其他肿瘤标志物相比，CA125 具有更高的预测价值（CA19-9，ROC 曲线下面积为 0.66，截断值为 289.40 U/mL；CA125，ROC 曲线下面积为 0.81，截断值为 19.70 U/mL）。此外，对于 CT 误判为可切除的不可切除疾病患者，CA125 超过所选截断值的百分比高于 CA19-9（CA19-9，70.27%；CA125，81.08%）。
结论
CA125 在预测胰腺癌可切除性方面优于 CA19-9。CA125 水平异常升高可能提示不可切除的胰腺癌。
Zotero 插件